Spots Global Cancer Trial Database for Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC
Official Title: A Prospective, Open-label, Single-arm Study for Efficacy and Safety of Three-drug Antiemetic Regimen to Prevent the Emesis During Radiotherapy With Concurrent Chemoradiotherapy in Locally Advanced HNSCC
Study ID: NCT03572829
Interventions
Study Description
Brief Summary: To evaluate the safety and efficacy of aprepitant combined with ondansetron and dexamethasone to prevent nausea and vomiting induced by Intensity-modulated Radiotherapy (IMRT) cisplatin-chemotherapy regimen in locally advanced squamous cell carcinoma of head and neck
Detailed Description: To evaluate the complete response rate, nause-free rate, vomiting-free rate, and the quality of life of aprepitant combined with ondansetron and dexamethasone for the nausea and vomiting induced by chemoradiotherapy in HNSCC.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
National Cancer Center/ Cancer Hospital, Chinese Academy of Medcal science and Peking Union Medical College, Beijing, , China
Contact Details
Name: Junlin Yi, M.D.
Affiliation: National Cancer Center/ Cancer Hospital, Chinese Academy of Medcal science and Peking Union Medical College
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
